Merck & Co., Inc. (BVMF:MRCK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 1.53T +38.2% |
| Revenue (ttm) | 343.09B +2.9% |
| Net Income | 46.61B -48.8% |
| EPS | 18.65 -48.0% |
| Shares Out | n/a |
| PE Ratio | 32.80 |
| Forward PE | 19.22 |
| Dividend | 1.40 (1.80%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,313 |
| Open | 77.11 |
| Previous Close | 76.93 |
| Day's Range | 76.04 - 77.97 |
| 52-Week Range | 51.86 - 80.23 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Transformation is ahead of schedule, with strong progress in oncology, HIV, and ophthalmology. The pipeline is robust, featuring differentiated ADCs, mRNA therapies, and novel cardiometabolic and immunology assets, with over 20 late-stage assets expected to drive significant growth.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, ...
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary...
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the...
Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
SAN DIEGO--(BUSINESS WIRE)-- #animalhealth--Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health.
Merck settles most Gardasil suits for over $50M, Bloomberg says
Merck (MRK) told Bloomberg in an emailed statement that it will pay more than $50M to settle over 200 lawsuits relating to its Gardasil HPV vaccine. The deal resolves a…
Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026
Recent phase III data in NSCLC and melanoma highlight durable efficacy for new combinations, while dose optimization and improved AE management support broader use of ADCs. Strategic acquisitions and partnerships are expanding the pipeline in CML and multiple solid tumors, with a strong focus on data-driven development.
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Merck & Co. Transcript: Investor update
Significant progress was highlighted in oncology, with KEYTRUDA's expansion into earlier-stage indications, a diversified late-stage pipeline, and strong clinical data for sac-TMT and other novel assets. Commercial momentum is robust, with new launches and a projected $25B+ opportunity by the mid-2030s.
Merck & Co. Press release: Investor update
Merck & Co. issued a press release on June 1, 2026, disclosing material business information to investors.
Merck & Co. Slides: Investor update
Merck & Co. has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Merck exec says company is discussing use of COVID antiviral drug in Ebola response
Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available as an Ebola treatment to address the widening outbreak in the Democratic Re...
Moderna, Merck to present 5-year data for intismeran autogene
Moderna (MRNA) and Merck (MRK), known as MSD outside of the United States and Canada, announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA...
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurr...
Merck says FDA grants Breakthrough Therapy Designation for calderasib
Merck (MRK) announced that calderasib, an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation ...
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C in...
Merck to Participate in the Jefferies Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference.
Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.
Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster — but VP of Digital Platforms Sean Finnerty says the only reason it's working i...
Merck chicken bronchitis vaccine approved for use in China
Merck said its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the world's largest chicken-rearing country, which is home to over 5 billion ...
Merck Announces Third-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2026 Dividend.
Merck & Co. Transcript: AGM 2026
The meeting highlighted strong financial growth, a robust late-stage pipeline, and major investments in R&D and manufacturing. All board nominees and management proposals were approved, while shareholder proposals on DEI, healthcare coverage, and political contributions were not.
Merck & Co. Slides: FY 2026
Merck & Co. has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 26, 2026.
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...